Showing results (41-50 of 50) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Lipid Research|May 12, 2010
Biochemical characterization of cholesteryl ester transfer protein inhibitorsMollie Ranalletta, Kathleen K Bierilo, Ying Chen, et al.Nature Cancer|August 23, 2024
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Guo Wei, Michael Serrano-Wu, et al.Bioorganic & Medicinal Chemistry|December 1, 2010
ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher doseEster Carballo-Jane, Zhu Chen, Edward O'Neill, et al.Journal of Lipid Research|October 30, 2012
Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosisAlison M Strack, Ester Carballo-Jane, Sheng-Ping Wang, et al.The Journal of Biological Chemistry|February 23, 2010
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptakeYan G Ni, Jon H Condra, Laura Orsatti, et al.Circulation|May 15, 2026
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive PatientsRick B Vega, Gavin O'Mahony, April M Barbour, et al.Journal of Lipid Research|October 21, 2010
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivoYan G Ni, Stefania Di Marco, Jon H Condra, et al.Circulation. Cardiovascular Genetics|December 18, 2012
The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humansRoshni R Singaraja, Suthesh Sivapalaratnam, Kees Hovingh, et al.Cell Chemical Biology|October 27, 2019
From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9Whitney L Petrilli, Gregory C Adam, Roman S Erdmann, et al.International Journal of Biological Sciences|February 23, 2012
An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genesLiwen Zhang, Timothy McCabe, Jon H Condra, et al.Pageof 5